Literature DB >> 20309701

[Spondyloarthritis and quality of life].

J Hermann1.   

Abstract

To measure the disease activity of spondyloarthritides (SpA), quality of life is assessed in addition to inflammation and functional impairment. To measure quality of life in ankylosing spondylitis (AS), the generic measurement instruments SF-36, SF-12 and EQ-5D are available in German, whereby the SF-36 is the instrument primarily used in clinical investigations. Compared to the normal population, AS patients experience a reduced quality of life. In woman and patients with a poor educational background, quality of life was particularly reduced.Measuring quality of life is also a generally recognised part of evaluating psoriasis arthritis (PsA), for which only SF-36 and EQ-5D are available in German-speaking countries. The instrument most frequently used in clinical studies is SF-36. The quality of life in PsA patients, in terms of both physical and mental components, was found to be significantly lower than in the normal population. Although PsA patients shared a similar reduction in quality of life to AS patients, they nevertheless enjoyed a better quality of life than rheumatoid arthritis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20309701     DOI: 10.1007/s00393-009-0572-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  46 in total

1.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Authors:  D D Gladman; P J Mease; M A Cifaldi; R J Perdok; E Sasso; J Medich
Journal:  Ann Rheum Dis       Date:  2006-10-17       Impact factor: 19.103

2.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

3.  Outcome measures in psoriatic arthritis.

Authors:  Dafna D Gladman; Philip J Mease; Paul Healy; Philip S Helliwell; Oliver Fitzgerald; Alberto Cauli; Ennio Lubrano; Gerald G Krueger; Désirée van der Heijde; Douglas J Veale; Arthur Kavanaugh; Peter Nash; Christopher Ritchlin; William Taylor; Vibeke Strand
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

4.  Validity, reliability, and sensitivity to change of a French version of the arthritis impact measurement scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate.

Authors:  J Pouchot; F Guillemin; J Coste; C Brégeon; J Sany
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

5.  Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration.

Authors:  M A Stone; E Pomeroy; A Keat; R Sengupta; S Hickey; P Dieppe; R Gooberman-Hill; R Mogg; J Richardson; R D Inman
Journal:  Rheumatology (Oxford)       Date:  2008-06-06       Impact factor: 7.580

6.  The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.

Authors:  A P Anandarajah; E M Schwarz; S Totterman; J Monu; C Y Feng; T Shao; S A Haas-Smith; C T Ritchlin
Journal:  Ann Rheum Dis       Date:  2007-10-29       Impact factor: 19.103

7.  [Ankylosing spondylitis in Central and Eastern Europe. Cross-sectional study on treatment modalities, disease activity and quality of life].

Authors:  W Ebner; T Palotai; C Codreanu; P Géher; A Pahor; K Pavelka; J Smolen; J Szechiński; M Zlnay
Journal:  Z Rheumatol       Date:  2008-10       Impact factor: 1.372

8.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors:  Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal:  Arthritis Rheum       Date:  2009-04

9.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors:  J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2003-06

10.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.

Authors:  Fausto Salaffi; Marina Carotti; Stefania Gasparini; Michele Intorcia; Walter Grassi
Journal:  Health Qual Life Outcomes       Date:  2009-03-18       Impact factor: 3.186

View more
  1 in total

1.  Sleep quality and associated factors in ankylosing spondylitis: relationship with disease parameters, psychological status and quality of life.

Authors:  İbrahim Batmaz; Mustafa Akif Sarıyıldız; Banu Dilek; Yasin Bez; Mehmet Karakoç; Remzi Çevik
Journal:  Rheumatol Int       Date:  2012-09-02       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.